About Aaron Royston, M.D.
Form D filings for Candid Therapeutics in 2024 list Aaron Royston, M.D. as director.
Aaron Royston, M.D. first appears on SEC filings in 2024.
Experience
This experience comes from SEC filings. The years are when the filings name Aaron Royston, M.D. in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Aaron Royston, M.D. works with at each company, as listed on that company's latest Form D.
Candid Therapeutics, Inc. · Form D, Sep 13, 2024
JD
Jeffrey Tong, Ph.D.
Director
AK
Arvind Kush
Executive officer
TD
Timothy Lu, M.D.
Executive officer
KD
Kenneth Song, M.D.
President and CEO, director
BD
Bernie Huyghe, Ph.D.
Executive officer
MD
Michael Rome, M.D.
Director